Frankfurt - Delayed Quote EUR
Arcadia Biosciences, Inc. (17D.F)
3.7200
0.0000
(0.00%)
As of February 24 at 8:06:54 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 1.3M | 1.6M | 6.5M | 7.9M |
| Low Estimate | 1.3M | 1.6M | 6.5M | 7.9M |
| High Estimate | 1.3M | 1.6M | 6.5M | 7.9M |
| Year Ago Sales | 1.25M | 1.31M | 5.04M | 6.5M |
| Sales Growth (year/est) | 3.59% | 22.51% | 28.84% | 21.54% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 17D.F | -- | -- | -- | -- |
| S&P 500 | 10.31% | 3.92% | 8.21% | 13.85% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/21/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/28/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/24/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 6/5/2023 |